Publication date: Mar 19, 2020
The FDA granted breakthrough device designation to the NeuroStar Advanced Therapy System for the treatment of bipolar depression, according to a press release from Neuronetics Inc. , the device’s manufacturer.
According to Tropsha, prior therapies typically have focused on treating the mania and hypomania phase of bipolar disorder, and only a few medications have been approved for the depression phase.
Since receiving FDA clearance in 2008, over 75,000 patients with depression have been treated with NeuroStar, with over 2. 5 million treatments performed.
|disease||MESH||major depressive disorder|